From: The prognostic significance of duodenal wall invasion in pancreatic adenocarcinoma
Characteristics | No. of patients | Progression-free survival | Overall survival | |||
---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |||
Age (y) | ≤ 60 (reference) | 26 | ||||
> 60 | 71 | 6.37 (1.63–24.81) | 0.008* | 7.06 (1.76–28.32) | 0.006* | |
Gender | Female (reference) | 39 | ||||
Male | 58 | 1.34 (0.48–3.73) | 0.57 | 1.29(0.46–3.69) | 0.63 | |
Race | White (reference) | 70 | ||||
African American | 12 | 5.17 (1.62–16.58) | 0.006* | 5.96 (1.84–19.27) | 0.003* | |
Other | 6 | 2.92 (0.49–17.41) | 0.24 | 2.59 (0.39–17.00) | 0.32 | |
Tumor stage | T1 (reference) | 20 | ||||
T2 | 53 | 0.53 (0.15–1.89) | 0.96 | 0.59 (0.16–2.19) | 0.43 | |
T3 | 24 | 0.89 (0.23–3.43) | 0.87 | 1.06 (0.27–4.18) | 0.94 | |
Tumor grading | G1 | 5 | ||||
G2 | 67 | 0.90(0.14–5.55) | 0.91 | 1.01 (0.16–6.36) | 0.99 | |
G3 | 25 | 2.21 (0.32–15.11) | 0.42 | 1.99 (0.28–14.09) | 0.49 | |
Lymph node involved | No (reference) | 26 | ||||
Yes | 71 | 2.05 (0.43–9.78) | 0.37 | 1.89 (0.39–9.20) | 0.43 | |
Duodenal invasion | Negative (reference) | 44 | ||||
Positive | 53 | 0.16 (0.05–0.56) | 0.004* | 0.19 (0.05–0.64) | 0.008* | |
Lymphovascular invasion | Negative (reference) | 27 | ||||
Positive | 70 | 1.20 (0.25–5.65) | 0.82 | 0.98 (0.21–4.58) | 0.98 | |
Perineural invasion | Negative (reference) | 15 | ||||
Positive | 82 | 0.48 (0.12–1.95) | 0.31 | 0.55 (0.14–2.21) | 0.39 | |
Ampullary invasion | Negative (reference) | 63 | ||||
Positive | 34 | 3.39 (0.79–14.45) | 0.09 | 2.77 (0.66–11.69) | 0.17 | |
CBD invasion | Negative (reference) | 79 | ||||
Positive | 18 | 0.94 (0.22–4.02) | 0.93 | 0.91 (0.21–3.85) | 0.89 | |
Margin status | Negative (reference) | 68 | ||||
Positive | 29 | 1.45(0.59–3.51) | 0.41 | 1.44 (0.58–3.56) | 0.43 |